Dyne Therapeutics Inc

DYN

Company Profile

  • Business description

    Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

  • Contact

    1560 Trapelo Road
    WalthamMA02451
    USA

    T: +1 781 786-8230

    E: [email protected]

    https://www.dyne-tx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    206

Stocks News & Analysis

stocks

Nvidia: Collaboration with Intel might bring some goodwill with the US

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks

What now for Santos after takeover offer collapses?

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks

Morningstar initiates coverage on small cap ASX REIT

Coverage of ASX listed REIT as investor interest in property continues to grow.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,061.2020.50-0.23%
CAC 407,853.591.02-0.01%
DAX 4023,639.4135.12-0.15%
Dow JONES (US)46,315.27172.850.37%
FTSE 1009,216.6711.44-0.12%
HKSE26,545.100.250.00%
NASDAQ22,631.48160.750.72%
Nikkei 22545,045.81257.62-0.57%
NZX 50 Index13,231.66111.630.85%
S&P 5006,664.3632.400.49%
S&P/ASX 2008,773.5018.70-0.21%
SSE Composite Index3,820.0911.57-0.30%

Market Movers